{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:44Z","timestamp":1788316844598,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["116283"],"award-info":[{"award-number":["116283"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11606-024-08793-9","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T14:02:56Z","timestamp":1715004176000},"page":"1870-1879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Helen","family":"Tesfaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke E.","family":"Zabotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Wexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Schmedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Koeneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Seman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-9898","authenticated-orcid":false,"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"issue":"12","key":"8793_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u2013772. https:\/\/doi.org\/10.1038\/s41569-020-0406-8.","journal-title":"Nat Rev Cardiol."},{"issue":"1","key":"8793_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/med.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73\u201379. https:\/\/doi.org\/10.1097\/med.0000000000000311.","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"8793_CR3","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.amjcard.2019.10.028","volume":"124","author":"S Verma","year":"2019","unstructured":"Verma S. Potential mechanisms of sodium-glucose co-transporter 2 inhibitor-related cardiovascular benefits. Am J Cardiol. 2019;124:S36\u2013S44. https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.028.","journal-title":"Am J Cardiol."},{"issue":"21","key":"8793_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med."},{"issue":"9","key":"8793_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/s2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691\u2013704. https:\/\/doi.org\/10.1016\/s2213-8587(18)30141-4.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"24","key":"8793_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med."},{"issue":"2","key":"8793_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.13101","volume":"20","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458\u2013462. https:\/\/doi.org\/10.1111\/dom.13101.","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"8793_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dom.14559","volume":"24","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Inzucchi SE, Mattheus M, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022;24(1):135\u2013141. https:\/\/doi.org\/10.1111\/dom.14559.","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"8793_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jchf.2019.08.004","volume":"8","author":"J Li","year":"2020","unstructured":"Li J, Woodward M, Perkovic V, et al. Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. JACC Heart Fail. 2020;8(1):57\u201366. https:\/\/doi.org\/10.1016\/j.jchf.2019.08.004.","journal-title":"JACC Heart Fail."},{"issue":"3","key":"8793_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","volume":"98","author":"J Li","year":"2020","unstructured":"Li J, Neal B, Perkovic V, et al. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int. 2020;98(3):769\u2013777. https:\/\/doi.org\/10.1016\/j.kint.2020.04.051.","journal-title":"Kidney Int."},{"issue":"2","key":"8793_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2337\/dc07-1276","volume":"31","author":"A Dehghan","year":"2008","unstructured":"Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31(2):361\u2013362. https:\/\/doi.org\/10.2337\/dc07-1276.","journal-title":"Diabetes Care."},{"issue":"5","key":"8793_CR12","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","volume":"53","author":"M Madero","year":"2009","unstructured":"Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796\u2013803. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.021.","journal-title":"Am J Kidney Dis."},{"issue":"9","key":"8793_CR13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221\u20132228. https:\/\/doi.org\/10.1093\/ndt\/gft029.","journal-title":"Nephrol Dial Transplant."},{"issue":"7","key":"8793_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380\u2013390. https:\/\/doi.org\/10.1038\/s41584-020-0441-1.","journal-title":"Nat Rev Rheumatol."},{"key":"8793_CR15","doi-asserted-by":"publisher","unstructured":"Safiri S, Kolahi AA, Cross M, et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990\u20132017: a systematic analysis of the global burden of disease study 2017. Arthritis Rheumatol. 72(11):1916\u20131927. https:\/\/doi.org\/10.1002\/art.41404.","DOI":"10.1002\/art.41404"},{"issue":"13","key":"8793_CR16","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200\u20131210. https:\/\/doi.org\/10.1056\/NEJMoa1710895.","journal-title":"N Engl J Med."},{"issue":"1","key":"8793_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.103","volume":"3","author":"E Patorno","year":"2020","unstructured":"Patorno E, Najafzadeh M, Pawar A, et al. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinol Diabetes Metab. 2020;3(1):e00103. https:\/\/doi.org\/10.1002\/edm2.103.","journal-title":"Endocrinol Diabetes Metab."},{"key":"8793_CR18","doi-asserted-by":"publisher","unstructured":"Association AD. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021. Diabetes Care. 2020;44(Supplement_1):S111\u2013S124. https:\/\/doi.org\/10.2337\/dc21-S009.","DOI":"10.2337\/dc21-S009"},{"issue":"5","key":"8793_CR19","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/dom.13223","volume":"20","author":"L Tonneijck","year":"2018","unstructured":"Tonneijck L, Muskiet MHA, Smits MM, et al. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: post-hoc analyses of four clinical trials. Diabetes Obes Metab. 2018;20(5):1235\u20131245. https:\/\/doi.org\/10.1111\/dom.13223.","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"8793_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105\u2013113. https:\/\/doi.org\/10.1016\/S2213-8587(17)30412-6.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"8793_CR21","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/pds.4044","volume":"25","author":"LA MacFarlane","year":"2016","unstructured":"MacFarlane LA, Liu CC, Solomon DH, Kim SC. Validation of claims-based algorithms for gout flares. Pharmacoepidemiol Drug Saf. 2016;25(7):820-6. https:\/\/doi.org\/10.1002\/pds.4044.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"8793_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12891-015-0614-2","volume":"16","author":"M Dehlin","year":"2015","unstructured":"Dehlin M, Stasinopoulou K, Jacobsson L. Validity of gout diagnosis in Swedish primary and secondary care\u2009-\u2009a validation study. BMC Musculoskelet Disord. 2015;16(1):149. https:\/\/doi.org\/10.1186\/s12891-015-0614-2.","journal-title":"BMC Musculoskelet Disord."},{"issue":"3","key":"8793_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.7326\/M19-2610","volume":"172","author":"M Fralick","year":"2020","unstructured":"Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172(3):186\u2013194. https:\/\/doi.org\/10.7326\/M19-2610.","journal-title":"Ann Intern Med."},{"issue":"12","key":"8793_CR24","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1681\/ASN.2021070988","volume":"32","author":"C Delgado","year":"2021","unstructured":"Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol. 2021;32(12):2994\u20133015. https:\/\/doi.org\/10.1681\/ASN.2021070988.","journal-title":"J Am Soc Nephrol."},{"issue":"8 Pt 2","key":"8793_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.7326\/0003-4819-127-8_part_2-199710151-00064","volume":"127","author":"DB Rubin","year":"1997","unstructured":"Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757\u2013763. https:\/\/doi.org\/10.7326\/0003-4819-127-8_part_2-199710151-00064.","journal-title":"Ann Intern Med."},{"issue":"9","key":"8793_CR26","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/aje\/kwy078","volume":"187","author":"JE Ripollone","year":"2018","unstructured":"Ripollone JE, Huybrechts KF, Rothman KJ, Ferguson RE, Franklin JM. Implications of the propensity score matching paradox in pharmacoepidemiology. Am J Epidemiol. 2018;187(9):1951\u20131961. https:\/\/doi.org\/10.1093\/aje\/kwy078.","journal-title":"Am J Epidemiol."},{"issue":"5","key":"8793_CR27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575\u2013584. https:\/\/doi.org\/10.1016\/j.cjca.2017.12.005.","journal-title":"Can J Cardiol."},{"issue":"5","key":"8793_CR28","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2215\/CJN.11480821","volume":"17","author":"DLS Suijk","year":"2022","unstructured":"Suijk DLS, van Baar MJB, van Bommel EJM, et al. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin J Am Soc Nephrol. 2022;17(5):663\u2013671. https:\/\/doi.org\/10.2215\/CJN.11480821.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"36","key":"8793_CR29","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","volume":"43","author":"W Doehner","year":"2022","unstructured":"Doehner W, Anker SD, Butler J, et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J. 2022;43(36):3435\u20133446. https:\/\/doi.org\/10.1093\/eurheartj\/ehac320.","journal-title":"Eur Heart J."},{"issue":"4","key":"8793_CR30","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","volume":"1","author":"J Li","year":"2019","unstructured":"Li J, Badve SV, Zhou Z, et al. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatol. 2019;1(4):e220\u2013e228. https:\/\/doi.org\/10.1016\/S2665-9913(19)30078-5.","journal-title":"Lancet Rheumatol."},{"key":"8793_CR31","doi-asserted-by":"publisher","DOI":"10.7326\/M23-0724","author":"N McCormick","year":"2023","unstructured":"McCormick N, Yokose C, Wei J, et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent gout flares and gout-primary emergency department visits and hospitalizations : a general population cohort study. Ann Intern Med. 2023. https:\/\/doi.org\/10.7326\/M23-0724.","journal-title":"Ann Intern Med."},{"issue":"11","key":"8793_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.35353","volume":"4","author":"MC Chung","year":"2021","unstructured":"Chung MC, Hung PH, Hsiao PJ, et al. Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in taiwan. JAMA Netw Open. 2021;4(11):e2135353. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.35353.","journal-title":"JAMA Netw Open."},{"issue":"10","key":"8793_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","volume":"5","author":"JM Loree","year":"2019","unstructured":"Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1870.","journal-title":"JAMA Oncol."},{"key":"8793_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","volume":"16","author":"T Kennedy-Martin","year":"2015","unstructured":"Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. https:\/\/doi.org\/10.1186\/s13063-015-1023-4.","journal-title":"Trials."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-08793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-024-08793-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-08793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:06:34Z","timestamp":1764266794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-024-08793-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["8793"],"URL":"https:\/\/doi.org\/10.1007\/s11606-024-08793-9","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"HT, KW, LZ, and JP have no conflicts of interest to disclose.EP was supported by research grants from the Patient Centered Outcomes Research Institute (DB-2020C2-20326) and the Food and Drug Administration (5U01FD007213), not related to the topic of this work.DW reports serving on Data Monitoring Committees for Novo Nordisk.LK is an employee of Eli Lilly and Company and owns stock in Eli Lilly and Company.NS and LS are employees of Boehringer-Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}